This episode explores antifungal pharmacology within the structural complexity of eukaryotic pathogens. Drawing from Murray’s Chapter 61, it examines how therapeutic strategy is shaped by the similarities between fungal and human cells.

Because fungi are eukaryotic, drug selectivity must target features unique to fungal biology. The episode organises antifungal agents by mechanism:

* Polyenes (e.g., amphotericin B) - bind ergosterol and disrupt membranes

* Azoles - inhibit ergosterol synthesis

* Echinocandins - inhibit β-glucan synthesis in the fungal cell wall

* Flucytosine - interferes with nucleic acid synthesis

* Allylamines - inhibit early steps in ergosterol production

Therapeutic choice depends on:

* Site of infection

* Host immune status

* Fungal species

* Drug toxicity profile

Conceptually, antifungal therapy is a balancing act between efficacy and host safety. Clinically, early targeted therapy is essential in invasive infections.

Key Takeaways

* Fungal therapy targets ergosterol and cell wall components

* Eukaryotic similarity limits drug selectivity

* Echinocandins target β-glucan synthesis

* Amphotericin B disrupts fungal membranes

* Drug selection depends on host and infection site

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe